Yes, binding sites can serve as biomarkers for cancer diagnosis and prognosis. The presence of specific binding sites or their mutations can indicate the type and stage of cancer. For example, the HER2 receptor, which has a well-characterized binding site, is overexpressed in some breast cancers and can be targeted for both diagnosis and therapy.
